Screener
AnaptysBio, Inc. ANAB Biopharma Company — Nonoperating Income Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Biopharma | Royalty Management | Total |
|---|---|---|---|
| (Loss) income from operations | (52,811) | 18,174 | (34,637) |
| Interest income | 2,328 | 325 | 2,653 |
| Non-cash interest expense | — | (20,859) | (20,859) |
| Other expense, net | (1) | — | (1) |
| Total other income (expense), net | 2,327 | (20,534) | (18,207) |
| Loss before income taxes | (50,484) | (2,360) | (52,844) |
| Provision for income taxes | — | (40) | (40) |
| Segment net loss | (50,484) | (2,400) | (52,884) |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s biopharma company — nonoperating income expense?
- AnaptysBio, Inc. (ANAB) reported biopharma company — nonoperating income expense of $2.33M in Q1 2026.
- How has AnaptysBio, Inc.'s biopharma company — nonoperating income expense changed year-over-year?
- AnaptysBio, Inc.'s biopharma company — nonoperating income expense decreased by 43.0% year-over-year, from $4.08M to $2.33M.
- What does biopharma company — nonoperating income expense mean?
- This metric aggregates all financial activities outside of the company's primary business operations, such as interest income, interest expense, and other non-operating items. It represents the net impact of the company's treasury and financing activities on its overall financial performance. This is a critical component for understanding the total net income or loss beyond operational results.
Ask your AI about AnaptysBio, Inc.'s biopharma company — nonoperating income expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude